1. Home
  2. KWR vs BEAM Comparison

KWR vs BEAM Comparison

Compare KWR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quaker Houghton

KWR

Quaker Houghton

N/A

Current Price

$120.92

Market Cap

2.3B

Sector

Industrials

ML Signal

N/A

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$25.42

Market Cap

2.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KWR
BEAM
Founded
1918
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.7B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
KWR
BEAM
Price
$120.92
$25.42
Analyst Decision
Buy
Buy
Analyst Count
5
16
Target Price
$152.50
$49.13
AVG Volume (30 Days)
156.2K
1.7M
Earning Date
05-26-2026
05-15-2026
Dividend Yield
1.68%
N/A
EPS Growth
N/A
82.31
EPS
N/A
N/A
Revenue
$1,888,634,000.00
$24,000.00
Revenue This Year
$5.05
N/A
Revenue Next Year
$4.03
$35.80
P/E Ratio
N/A
N/A
Revenue Growth
2.66
33.33
52 Week Low
$95.91
$13.53
52 Week High
$183.01
$36.44

Technical Indicators

Market Signals
Indicator
KWR
BEAM
Relative Strength Index (RSI) 18.27 42.32
Support Level $111.56 $23.84
Resistance Level $126.57 $25.69
Average True Range (ATR) 7.41 1.94
MACD -3.77 -0.23
Stochastic Oscillator 0.00 9.58

Price Performance

Historical Comparison
KWR
BEAM

About KWR Quaker Houghton

Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: